[{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HLS Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"HLS Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Porcine recombinant Factor VIII","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"HLS Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"HLS Therapeutics \/ HLS Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"HLS Therapeutics \/ HLS Therapeutics"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended-release Injectable Suspension","sponsorNew":"HLS Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HLS Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Amarin","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HLS Therapeutics \/ Amarin Corporation","highestDevelopmentStatusID":"10","companyTruncated":"HLS Therapeutics \/ Amarin Corporation"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HLS Therapeutics \/ HLS Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"HLS Therapeutics \/ HLS Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by HLS Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under terms of the Agreement, Pfizer will deploy a team across Canada to support education about Vascepa with primary care physician ("PCP") groups.

                          Brand Name : Vascepa

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 16, 2021

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Recipient : Pfizer Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Vascepa COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while demonstrating a 25% reduction in high-sensitivity C-reactive protein with encouraging short-term safety and tolerability data using Vascepa lo...

                          Brand Name : Vascepa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 14, 2020

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Amarin

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Health Canada has approved HLS Therapeutics' PERSERIS® (risperidone for extended-release injectable suspension), 90 mg and 120 mg subcutaneous injection, a novel long-acting injectable of risperidone, for the treatment of schizophrenia in adults.

                          Brand Name : Perseris

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 17, 2020

                          Lead Product(s) : Risperidone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : HLS has acquired certain entities that hold the rights to a diversified portfolio of royalty interests on global sales of four different products, this includes Takeda Pharmaceutical's Obizur, a porcine recombinant Factor VIII for acquired hemophilia A.

                          Brand Name : Obizur

                          Molecule Type : Large molecule

                          Upfront Cash : $30.8 million

                          September 30, 2020

                          Lead Product(s) : Porcine recombinant Factor VIII

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Recipient : Takeda Pharmaceutical

                          Deal Size : $49.3 million

                          Deal Type : Acquisition

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 23, 2020

                          Lead Product(s) : Risperidone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank